Prostate cancer metastatic

47 trials 21 recruiting MedDRA PT
47 Registered trials
21 Recruiting
32 Unique sponsors
41 Unique IMPs
38 Commercial trials
Drug classes (ATC)
— ATC code not specified 19
H Endocrinology (ATC H) 7
L Oncology (ATC L) 19
V Various (ATC V) 4
G Urology/Gynaecology (ATC G) 1
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 28 substances
PARP inhibitor 3 substances
Corticosteroid 2 substances
Taxane 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Radiopharmaceutical 1 substance
Antibody-drug conjugate (ADC) 1 substance
Statin 1 substance
Phase III: 22 Phase II: 9 Phase I/II: 4 Phase I: 5 Phase I (Other): 4 Phase I (First in Human): 2 Other: 1

Filter these 47 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 47 trials

Phase III

22 trials
  • A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial
    COPPER (64CU) CHLORIDE; FLUOROCHOLINE (18F)
    2025-520861-29-00 1 country n=285
    Pending
  • A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial
    COPPER (64CU) CHLORIDE
    2025-520868-17-00 1 country n=138
    Pending
  • Aragon Pharmaceuticals Inc. Commercial
    ABIRATERONE ACETATE; APALUTAMIDE
    2023-509221-47-00 12 countries 2014 n=30
    Ended
  • AstraZeneca AB Commercial
    CAPIVASERTIB; DOCETAXEL
    2023-504996-26-00 8 countries 2022 n=424
    Ended
  • Bayer Consumer Care AG Commercial
    DAROLUTAMIDE
    2022-502244-12-00 3 countries 2021 n=132
    Ended
  • European Organisation For Research And Treatment Of Cancer Commercial
    ENZALUTAMIDE; RADIUM RA 223 DICHLORIDE
    2023-510453-41-00 8 countries 2015 n=255
    Ended
  • Janssen - Cilag International Commercial
    ABIRATERONE ACETATE; NIRAPARIB; NIRAPARIB, ABIRATERONE ACETATE; PREDNISONE
    2023-503254-12-00 10 countries 2019 n=235
    Ended
  • Janssen - Cilag International Commercial
    ABIRATERONE ACETATE; NIRAPARIB; NIRAPARIB, ABIRATERONE ACETATE; PREDNISONE
    2023-506365-64-00 13 countries 2020 n=211
    Ended
  • Janssen - Cilag International Commercial
    ABIRATERONE ACETATE; APALUTAMIDE; PREDNISONE
    2023-508606-26-00 3 countries 2015 n=5
    Ended
  • Janssen - Cilag International Commercial
    APALUTAMIDE
    2023-508607-20-00 3 countries 2015 n=7
    Ended
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial
    4-((3-((5,6-DIHYDRO-2-(TRIFLUOROMETHYL)(1,2,4)TRIAZOLO(1,5-A)PYRAZIN-7(8H)-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)-1(2H)-PHTHALAZINONE; ABIRATERONE ACETATE; PREDNISONE
    2023-509396-16-00 6 countries 2021 n=136
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2022-500785-10-00 11 countries 2019 n=420
    Ended
  • Novartis Pharma AG Commercial
    GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    2022-502956-29-00 11 countries 2024 n=215
    Recruiting
  • Pfizer Inc. Commercial
    ENZALUTAMIDE
    2023-509087-20-00 12 countries 2019 n=411
    Ended
  • Pfizer Inc. Commercial
    ENZALUTAMIDE
    2024-510809-28-00 12 countries 2021 n=207
    Ended
  • Pfizer Inc. Commercial
    5,8-DICHLORO-2-[(4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL]-7-[(R)-METHOXY(OXETAN-3-YL)METHYL]-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE; ENZALUTAMIDE
    2024-511650-50-00 11 countries 2025 n=205
    Ended
  • Pfizer Inc. Commercial
    5,8-DICHLORO-2-[(4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL]-7-[(R)-METHOXY(OXETAN-3-YL)METHYL]-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE
    2024-511652-40-00 14 countries 2025 n=328
    Recruiting
  • Pfizer Inc. Commercial
    5,8-DICHLORO-2-[(4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL]-7-[(R)-METHOXY(OXETAN-3-YL)METHYL]-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE; ENZALUTAMIDE
    2024-519369-24-00 12 countries 2026 n=434
    Recruiting
  • Friedrich-Schiller-Universitaet Jena Academic
    BUSERELIN ACETATE; DAROLUTAMIDE; DEGARELIX; DOCETAXEL; GOSERELIN ACETATE; LEUPRORELIN ACETATE; RELUGOLIX
    2022-502634-52-00 2 countries 2023 n=280
    Ended
  • Karolinska Institutet Academic
    CAPIVASERTIB; DAROLUTAMIDE; NIRAPARIB, ABIRATERONE ACETATE
    2023-506857-40-00 3 countries 2019 n=1,750
    Recruiting
  • Pirkanmaan hyvinvointialue Academic
    ATORVASTATIN
    2024-515109-24-00 1 country 2023 n=240
    Recruiting
  • Unicancer Academic
    DAROLUTAMIDE
    2022-502425-18-00 10 countries 2022 n=288
    Recruiting

Phase II

9 trials
  • Astellas Pharma Global Development Inc. Commercial
    ENZALUTAMIDE
    2023-510298-33-00 15 countries 2016 n=251
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    CABAZITAXEL; IPILIMUMAB; NIVOLUMAB
    2022-502909-15-00 1 country 2017 n=69
    Ended
  • Debiopharm International S.A. Commercial
    DEGARELIX
    2024-511038-11-00 7 countries 2024 n=41
    Ended
  • F. Hoffmann-La Roche AG Commercial
    INAVOLISIB
    2025-521327-67-00 4 countries 2026 n=32
    Recruiting
  • UroTrials GmbH Commercial
    BMS-986365
    2025-523672-23-00 1 country n=42
    Pending
  • Fundación Oncosur Academic
    TALAZOPARIB
    2023-510536-37-00 2 countries 2024 n=103
    Recruiting
  • Hospices Civils De Lyon Academic
    GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    2024-512043-22-00 1 country 2025 n=58
    Recruiting
  • Universita' Degli Studi Di Torino Academic
    APALUTAMIDE
    2024-515049-41-00 1 country 2024 n=94
    Recruiting
  • Universitaet Muenster Academic
    DAROLUTAMIDE; TESTOSTERONE
    2025-521051-23-00 1 country 2025 n=60
    Recruiting

Phase I/II

4 trials
  • AstraZeneca AB Commercial
    ABIRATERONE ACETATE; APALUTAMIDE; DAROLUTAMIDE; ENZALUTAMIDE; PREDNISONE; SARUPARIB
    2023-508536-64-00 1 country 2022 n=50
    Ended
  • Celcuity Inc. Commercial
    DAROLUTAMIDE; DEXAMETHASONE; GEDATOLISIB
    2023-505898-32-00 2 countries 2024 n=40
    Recruiting
  • LAVA Therapeutics N.V. Commercial
    HUMANISED BISPECIFIC IMMUNOGLOBULIN VHH FRAGMENTS AGAINST PSMA AND VGAMMA9VDELTA2 T-CELL RECEPTOR; PEMBROLIZUMAB
    2024-515821-27-00 2 countries 2021 n=110
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IFINATAMAB DERUXTECAN; OPEVESOSTAT TOSILATE
    2024-516036-94-00 7 countries 2025 n=145
    Recruiting

Phase I

5 trials
  • Bayer AG Commercial
    IMP not specified
    2022-502623-22-00 4 countries 2023 n=90
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2025-521886-28-00 1 country 2026 n=15
    Recruiting
  • Genentech Inc. Commercial
    IMP not specified
    2023-504013-68-00 2 countries 2024 n=22
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2023-504063-17-00 2 countries 2024 n=71
    Recruiting
  • ORIC Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-515527-11-00 1 country 2025 n=48
    Recruiting

Phase I (Other)

4 trials
  • Arvinas Androgen Receptor Inc. Commercial
    IMP not specified
    2024-516661-37-00 1 country 2022 n=4
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2022-503132-14-00 1 country 2025 n=15
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    FLUDROCORTISONE; ODM-208 TOSILATE; PREDNISONE
    2023-505521-14-00 1 country 2023 n=14
    Ended

Phase I (First in Human)

2 trials
  • AstraZeneca AB Commercial
    6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; AZD0516
    2024-520026-11-00 3 countries 2026 n=107
    Recruiting
  • Pfizer Inc. Commercial
    PF-07220060 MONOHYDRATE
    2024-512120-11-00 2 countries 2022 n=62
    Ended

Other

1 trial
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic
    IMP not specified
    2024-513729-22-01 1 country 2022 n=30
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 6 Phase I, Phase I (Other), Phase III 2
Pfizer Inc. Commercial 6 Phase III, Phase I (First in Human) 2
Merck Sharp & Dohme LLC Commercial 3 Phase I (Other), Phase III, Phase I/II 1
AstraZeneca AB Commercial 3 Phase III, Phase I (First in Human), Phase I/II 1
A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial 2 Phase III 0
Bayer AG Commercial 1 Phase I 1
Daiichi Sankyo Inc. Commercial 1 Phase I 1
Genentech Inc. Commercial 1 Phase I 1
ORIC Pharmaceuticals Inc. Commercial 1 Phase I 1
Arvinas Androgen Receptor Inc. Commercial 1 Phase I (Other) 0
Exelixis Inc. Commercial 1 Phase I (Other) 0
Astellas Pharma Global Development Inc. Commercial 1 Phase II 0
Bristol Myers Squibb International Corporation Commercial 1 Phase II 0
Debiopharm International S.A. Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 1
UroTrials GmbH Commercial 1 Phase II 0
Aragon Pharmaceuticals Inc. Commercial 1 Phase III 0
Bayer Consumer Care AG Commercial 1 Phase III 0
European Organisation For Research And Treatment Of Cancer Commercial 1 Phase III 0
Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial 1 Phase III 0
New trials by year
2019
4
2020
1
2021
4
2022
6
2023
5
2024
7
2025
7
2026
4
← All indication landscapes